The Drugs Controller General of India (DGCI), the national drug regulator, approved the Zydus Cadila vaccine for emergency use on August 20. According to sources, the needle-free coronavirus vaccine ZyCoV-D may be available by early October.
This is the world’s first plasmid DNA vaccine for Covid-19. This is a triple dose vaccine given on days 0, 28, and 56. This vaccine is approved for use in adolescents between the ages of 12 and 18.
To expand the pool of COVID-19 vaccines in the country, Dr. Paul said the Hyderabad-based pharmaceutical company, Biological E’s COVID-19 vaccine Corbevax, and the COVID-19 mRNA vaccine are in the final stages of trial. rice field. “The other two vaccines are Corbevax, a COVID-19 vaccine from Biological E, which is in the final stages of trial. Its production is already underway. Similarly, there is an attractive mRNA vaccine from Genova. It’s in the final stages of things. Trials and this will also be available by the end of the year, “said NITIA ayog members.
He also said, “Bharat Biotech’s nasal vaccine and the externally developed US company Novabax’s vaccine will be stockpiled by the Serum Institute of India. The Emergency License (EUA) for this vaccine is still in place. Although not known, our trial is almost complete. “Currently, the Covishield, Covaxin, and Sputnik V vaccines are given to eligible populations over the age of 18.”
Dr. Paul added, “Other vaccines already in the portfolio include Sputnik V. Progress is a bit slow as this is a vaccine developed elsewhere. Technology is transferred here. Sputnik V has been administered to about 8. Individuals already at 90,000 rupees. “
“When a virus tries to mischief in the form of one vaccine, it is important that a pool of different vaccines is available, at least because there are other vaccines. Therefore, significant development is currently underway. The hard work done by the development team and the industry, and all the efforts the government has made in this regard. “Monday India crossed the” milestone “beyond India’s 75 Chlore mark. Cumulative COVID-19 vaccination rate.
Dr. Paul praised the country for its achievements: “We are very proud of this achievement, which rests on the shoulders of two vaccines manufactured in India, Covishield and Covaxin. Covaxin is being developed in India. ”
Discussions on pricing of Zydus Cadila’s COVID-19 vaccine are underway and will be decided shortly, Health News, ET HealthWorld
Source link Discussions on pricing of Zydus Cadila’s COVID-19 vaccine are underway and will be decided shortly, Health News, ET HealthWorld